Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer

Neoplasia (United States)

Volumn 15, Issue 7, 2013, Pages 761-772

  Terry, Stéphane ^a,b,c   Maillé, Pascale ^d   Baaddi, Habiba ^a,b   Kheuang, Laurence ^a,b   Soyeux, Pascale ^a,b   Nicolaiew, Nathalie ^a,b   Ceraline, Jocelyn ^e   Firlej, Virginie ^a,b   Beltran, Himisha ^f   Allory, Yves ^a,b,d   de la Taille, Alexandre ^a,b,d   Vacherot, Francis ^a,b  

^a INSERM U955   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c INSTITUT CURIE   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e UNIVERSITÉ DE STRASBOURG   (France)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CADHERIN; CAMPTOTHECIN; COMPLEMENTARY DNA; DOCETAXEL; KALLIKREIN 5; LUCIFERASE; MYC PROTEIN; PACLITAXEL; PHORBOL ESTER; PROTOCADHERIN PC; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER RESISTANCE; CARCINOGENESIS; CELL GROWTH; CELL TRANSDIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; DENSITOMETRY; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84879643103     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.122070     Document Type: Article

References (51)

1. Siegel R, Naishadham D, and Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin 62, 10-29.
2. Isaacs JT and Isaacs WB (2004). Androgen receptor outwits prostate cancer drugs. Nat Med 10, 26-27.
3. Denmeade SR and Isaacs JT (2002). A history of prostate cancer treatment. Nat Rev Cancer 2, 389-396.
4. Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, et al. (2011). New therapies for castration resistant prostate cancer: efficacy and safety. Eur Urol 60, 279-290.
5. Feldman BJ and Feldman D (2001). The development of androgen-independent prostate cancer. Nat Rev Cancer 1, 34-45.
6. Burchardt T, Burchardt M, Chen MW, Cao Y, de la Taille A, Shabsigh A, Hayek O, Dorai T, and Buttyan R (1999). Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 162, 1800-1805.
7. Wright ME, Tsai MJ, and Aebersold R (2003). Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol 17, 1726-1737.
8. Yuan TC, Veeramani S, Lin FF, Kondrikou D, Zelivianski S, Igawa T, Karan D, Batra SK, and Lin MF (2006). Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr Relat Cancer 13, 151-167.
9. Sauer CG, Roemer A, and Grobholz R (2006). Genetic analysis of neuroendocrine tumor cells in prostatic carcinoma. Prostate 66, 227-234.
10. Cindolo L, Cantile M, Vacherot F, Terry S, and de la Taille A (2007). Neuroendocrine differentiation in prostate cancer: from lab to bedside. Urol Int 79, 287-296.
11. Jiborn T, Bjartell A, and Abrahamsson PA (1998). Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology 51, 585-589.
12. di Sant'Agnese PA (1992). Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol 23, 287-296.
13. Chen MW, Vacherot F, De La Taille A, Gil-Diez-De-Medina S, Shen R, Friedman RA, Burchardt M, Chopin DK, and Buttyan R (2002). The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells. Oncogene 21, 7861-7871.
14. Blanco P, Sargent CA, Boucher CA, Mitchell M, and Affara NA (2000). Conservation of PCDHX in mammals; expression of human X/Y genes predominantly in brain. Mamm Genome 11, 906-914.
15. Yang X, Chen MW, Terry S, Vacherot F, Chopin DK, Bemis DL, Kitajewski J, Benson MC, Guo Y, and Buttyan R (2005). A human- and male-specific proto- cadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells. Cancer Res 65, 5263-5271.
16. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, and Murphy GP (1983). LNCaP model of human prostatic car- cinoma. Cancer Res 43, 1809-1818.
17. Terry S, Queires L, Gil-Diez-de-Medina S, Chen MW, de la Taille A, Allory Y, Tran PL, Abbou CC, Buttyan R, and Vacherot F (2006). Protocadherin-PC promotes androgen-independent prostate cancer cell growth. Prostate 66, 1100-1113.
18. Cleutjens KB, van der Korput HA, van Eekelen CC, van Rooij HC, Faber PW, and Trapman J (1997). An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol 11, 148-161.
19. Romijn JC, Verkoelen CF, and Schroeder FH (1988). Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects. Prostate 12, 99-110.
20. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, et al. (2011). Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 1, 487-495.
21. Terry S, Ploussard G, Allory Y, Nicolaiew N, Boissiere-Michot F, Maille P, Kheuang L, Coppolani E, Ali A, Bibeau F, et al. (2009). Increased expression of class III β-tubulin in castration-resistant human prostate cancer. Br J Cancer 101, 951-956.
22. van Steenbrugge GJ, van Uffelen CJ, Bolt J, and Schroder FH (1991). The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity. J Steroid Biochem Mol Biol 40, 207-214.
23. Chen M, Tanner M, Levine AC, Levina E, Ohouo P, and Buttyan R (2009). Androgenic regulation of hedgehog signaling pathway components in prostate cancer cells. Cell Cycle 8, 149-157.
24. Bernard D, Pourtier-Manzanedo A, Gil J, and Beach DH (2003). Myc confers androgen-independent prostate cancer cell growth. J Clin Invest 112, 1724-1731.
25. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, Brinkmann AO, and Mulder E (1992). The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 41, 665-669.
26. Masiello D, Cheng S, Bubley GJ, Lu ML, and Balk SP (2002). Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 277, 26321-26326.
27. Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, and Kyprianou N (2010). Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 70, 7992-8002.
28. Yang X, Chen MW, Terry S, Vacherot F, Bemis DL, Capodice J, Kitajewski J, de la Taille A, Benson MC, Guo Y, et al. (2006). Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells. Oncogene 25, 3436-3444.
29. Sramkoski RM, Pretlow TG II, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, and Jacobberger JW (1999). A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 35, 403-409.
30. Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, and Isaacs JT (2003). Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 54, 249-257.
31. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D, and Chinnaiyan AM (2002). α-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287, 1662-1670.
32. Deng X, Liu H, Huang J, Cheng L, Keller ET, Parsons SJ, and Hu CD (2008). Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res 68, 9663-9670.
33. Frigo DE and McDonnell DP (2008). Differential effects of prostate cancer thera- peutics on neuroendocrine transdifferentiation. Mol Cancer Ther 7, 659-669.
34. Day ML, Zhao X, Wu S, Swanson PE, and Humphrey PA (1994). Phorbol ester-induced apoptosis is accompanied by NGFI-A and c-fos activation in androgen-sensitive prostate cancer cells. Cell Growth Differ 5, 735-741.
35. Akao Y, Kusakabe S, Banno Y, Kito M, Nakagawa Y, Tamiya-Koizumi K, Hattori M, Sawada M, Hirabayasi Y, Ohishi N, et al. (2002). Ceramide accumulation is independent of camptothecin-induced apoptosis in prostate cancer LNCaP cells. Biochem Biophys Res Commun 294, 363-370.
36. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, et al. (2004). Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 64, 9209-9216.
37. Hirano D, Okada Y, Minei S, Takimoto Y, and Nemoto N (2004). Neuroendocrine differentiation in hormone refractory prostate cancer following andro- gen deprivation therapy. Eur Urol 45, 586-592; discussion 592.
38. Wafa LA, Palmer J, Fazli L, Hurtado-Coll A, Bell RH, Nelson CC, Gleave ME, Cox ME, and Rennie PS (2007). Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Hum Pathol 38, 161-170.
39. Bonkhoff H, Stein U, and Remberger K (1995). Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum Pathol 26, 167-170.
40. Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE, Veltri RW, Walsh PC, and Isaacs JT (1995). Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1, 473-480.
41. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, and Sawyers CL (2004). Molecular determinants of resistance to antiandrogen therapy. Nat Med 10, 33-39.
42. Heinlein CA and Chang C (2004). Androgen receptor in prostate cancer. Endocr Rev 25, 276-308.
43. Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gonen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, et al. (2010). Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol 34, 300-313.
44. Helpap B and Kollermann J (2001). Immunohistochemical analysis of the proliferative activity of neuroendocrine tumors from various organs. Are there in- dications for a neuroendocrine tumor-carcinoma sequence? Virchows Arch 438, 86-91.
45. Wang W and Epstein JI (2008). Small cell carcinoma of the prostate. A morpho- logic and immunohistochemical study of 95 cases. Am J Surg Pathol 32, 65-71.
46. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, et al. (2010). Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120, 2715-2730.
47. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, and Tindall DJ (2008). Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68, 5469-5477.
48. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, et al. (2009). Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69, 16-22.
49. Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, et al. (2010). An integrated network of androgen receptor, polycomb, and TMPRSS2- ERG gene fusions in prostate cancer progression. Cancer Cell 17, 443-454.
50. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, et al. (2011). Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19, 575-586.
51. Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, Hayward SW, Kasper S, and Matusik RJ (2004). NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res 64, 5489-5495.